| Stereochemistry | ABSOLUTE |
| Molecular Formula | C36H54N12O9 |
| Molecular Weight | 798.889 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=WVPOPWDCSFQEBI-HJJAOGADSA-N
InChI=1S/C36H54N12O9/c1-20(29(51)46-26(34(56)57)10-6-16-43-36(40)41)44-32(54)27(18-22-11-13-23(50)14-12-22)47-31(53)25(9-5-15-42-35(38)39)45-33(55)28(19-49)48-30(52)24(37)17-21-7-3-2-4-8-21/h2-4,7-8,11-14,20,24-28,49-50H,5-6,9-10,15-19,37H2,1H3,(H,44,54)(H,45,55)(H,46,51)(H,47,53)(H,48,52)(H,56,57)(H4,38,39,42)(H4,40,41,43)/t20-,24-,25-,26-,27-,28-/m0/s1
GM-602 (GM6) is a six-amino-acid active analog peptide of Motoneuronotrophic factor (MNTF). This compound is a small peptide that can cross the blood-brain barrier and has been shown to induce an embryonic-like neuroprotective microenvironment that helps detect and self-correct CNS- and neurodegenerative-related pathophysiology. Phase II clinical trials with GM-602, GM-604 and GM-608 have been completed to examine its potential in respectively stroke, Amyotrophic Lateral Sclerosis (ALS), and Parkinson’s disease.
Originator
Approval Year
ACTIVE MOIETY
